{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:28:06Z","timestamp":1794302886142,"version":"4.9.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajo.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:40:37Z","timestamp":1788565237000},"page":"436-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-World Applicability of Anti-VEGF Trial Criteria for Diabetic Macular Edema"],"prefix":"10.1016","volume":"292","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9454-6682","authenticated-orcid":false,"given":"Raj","family":"Kundu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6718-6768","authenticated-orcid":false,"given":"Nathan","family":"Goturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Poulaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole H.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju L.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-9476","authenticated-orcid":false,"given":"Steven","family":"Ness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2026.09.002_sbref0001","series-title":"Vision Loss and Diabetes","year":"2024"},{"issue":"11","key":"10.1016\/j.ajo.2026.09.002_bib0002","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-8587(20)30347-8","article-title":"Under the lens: diabetic retinopathy","volume":"8","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.002_bib0003","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","article-title":"Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis","volume":"67","author":"Im","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajo.2026.09.002_bib0004","series-title":"Developments in Ophthalmology","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000438970","article-title":"Diabetic retinopathy and diabetic macular edema","volume":"55","author":"Cohen","year":"2016"},{"issue":"13","key":"10.1016\/j.ajo.2026.09.002_bib0005","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.002_bib0006","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating Ranibizumab plus prompt or deferred laser or Triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.002_bib0008","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2026.09.002_bib0009","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"10432","key":"10.1016\/j.ajo.2026.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.ajo.2026.09.002_bib0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100111","article-title":"YOSEMITE and RHINE","volume":"2","author":"Eter","year":"2022","journal-title":"Ophthalmol Sci."},{"key":"10.1016\/j.ajo.2026.09.002_bib0013","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"issue":"9453","key":"10.1016\/j.ajo.2026.09.002_bib0014","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?","volume":"365","author":"Rothwell","year":"2005","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pctr.0010009","article-title":"Factors that can affect the external validity of randomised controlled trials","volume":"1","author":"Rothwell","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300236","article-title":"Broadening eligibility criteria and diversity among patients for cancer clinical trials","volume":"3","author":"Kaur","year":"2024","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.002_bib0017","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/ehf2.14767","article-title":"Eligibility for vericiguat in a real-world, contemporary heart failure population","volume":"11","author":"Vergaro","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0303348","article-title":"Eligibility for omecamtiv mecarbil in a real-world heart failure population: data from the Swedish Heart Failure Registry. Higuchi S, Ed","volume":"19","author":"Lindberg","year":"2024","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.002_bib0019","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/IAE.0000000000002476","article-title":"Pragmatism of randomized clinical trials on ranibizumab for the treatment of diabetic macular edema: impact on clinical outcomes","volume":"40","author":"Stewart","year":"2020","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-089801","article-title":"Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study","volume":"15","author":"Westborg","year":"2025","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.002_bib0021","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"10326","key":"10.1016\/j.ajo.2026.09.002_bib0022","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"The Lancet"},{"issue":"9","key":"10.1016\/j.ajo.2026.09.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70198","article-title":"TriNetX Dataworks-USA: overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US Census","volume":"34","author":"Stein","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.002_bib0024","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoint.2026.100250","article-title":"Eligibility criteria in RCTs of anti-VEGF therapy for diabetic macular edema: a systematic review","volume":"3","author":"Junior","year":"2026","journal-title":"AJO Int"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoint.2025.100124","article-title":"Evidence for whom? A systematic review of eligibility criteria in RCTs of anti-VEGF for neovascular age-related macular degeneration","volume":"2","author":"Arnold-Vangsted","year":"2025","journal-title":"AJO Int"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoint.2026.100227","article-title":"A systematic review of eligibility criteria in randomized controlled trials of anti-VEGF therapy for retinal vein occlusion","volume":"3","author":"Christensen","year":"2026","journal-title":"AJO Int"},{"issue":"12","key":"10.1016\/j.ajo.2026.09.002_bib0028","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1007\/s12325-022-02326-8","article-title":"Outcomes of over 40,000 eyes treated for diabetic macula edema in routine clinical practice: a systematic review and meta-analysis","volume":"39","author":"Mehta","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.002_bib0029","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2026.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.002_bib0031","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jamaophthalmol.2021.0857","article-title":"Racial\/ethnic disparities in ophthalmology clinical trials resulting in US Food and Drug Administration Drug approvals from 2000 to 2020","volume":"139","author":"Berkowitz","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.002_bib0032","first-page":"123","article-title":"Race and ethnic representation among clinical trials for diabetic retinopathy and diabetic macular edema within the United States: a review","volume":"114","author":"Sanjiv","year":"2022","journal-title":"J Natl Med Assoc"},{"issue":"9","key":"10.1016\/j.ajo.2026.09.002_bib0033","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1345\/aph.1E685","article-title":"Ethnic disparities: control of glycemia, blood pressure, and LDL cholesterol among US adults with type 2 diabetes","volume":"39","author":"Kirk","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.002_bib0034","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12020-012-9744-6","article-title":"Glucose control in diabetes: the impact of racial differences on monitoring and outcomes","volume":"42","author":"Campbell","year":"2012","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.002_bib0035","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/HYPERTENSIONAHA.121.18086","article-title":"Racial and ethnic differences in blood pressure among US adults, 1999\u20132018","volume":"78","author":"Hardy","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.002_bib0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11886-022-01826-x","article-title":"Racial and ethnic disparities in hypertension: barriers and opportunities to improve blood pressure control","volume":"25","author":"Abrahamowicz","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ajo.2026.09.002_bib0037","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Enhancing participation in clinical trials\u2014eligibility criteria, enrollment practices, and trial designs (FDA-2019-D-1264). 2025. Accessed March 21, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs."},{"key":"10.1016\/j.ajo.2026.09.002_bib0038","series-title":"Emergent Health Communication Scholarship From and About African American, Latino\/a\/x, and American Indian\/Alaskan Native Peoples","first-page":"19","article-title":"Community-based participatory research (CBPR) to enhance participation of racial\/ethnic minorities in clinical trials: a 10-year systematic review","author":"Julian McFarlane","year":"2023"},{"issue":"11","key":"10.1016\/j.ajo.2026.09.002_bib0039","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jamaophthalmol.2023.4638","article-title":"Diverse research teams and underrepresented groups in clinical studies","volume":"141","author":"Bains","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.002_bib0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s44440-025-00002-8","article-title":"Racial and ethnic diversity in ophthalmology: a meta-analysis of industry-sponsored phase 3 clinical trials from a single company","volume":"1","author":"Scott","year":"2025","journal-title":"Eye Open"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.002_bib0041","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","article-title":"A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections","volume":"31","author":"Van Der Reis","year":"2011","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.002_bib0042","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ekir.2024.02.003","article-title":"Effect of intravitreal anti-endothelial growth factor agents on renal function in patients with diabetes mellitus","volume":"9","author":"Rivero","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1016\/j.ajo.2026.09.002_bib0043","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s13300-025-01791-y","article-title":"Evidence-based guidelines for intravitreal anti-VEGF therapy for diabetic retinopathy in chronic kidney disease","volume":"16","author":"Sharma","year":"2025","journal-title":"Diabetes Ther"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.002_bib0044","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3390\/medicina58081081","article-title":"Changes of estimated glomerular filtration rate and glycated hemoglobin A1c in diabetic macular edema patients treated by ranibizumab and aflibercept in the tertiary referral hospital","volume":"58","author":"Ku","year":"2022","journal-title":"Medicina (Mex)"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.002_bib0045","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12882-019-1650-1","article-title":"Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease","volume":"20","author":"O\u2019Neill","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ajo.2026.09.002_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1691597","article-title":"Effect of intravitreal VEGF inhibitors on renal-related adverse events in patients with diabetes mellitus: systematic review and meta-analysis","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Pharmacol"},{"issue":"19","key":"10.1016\/j.ajo.2026.09.002_bib0047","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.002_bib0048","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.002_bib0049","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/eye.2008.360","article-title":"The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension","volume":"23","author":"Rasier","year":"2009","journal-title":"Eye"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2008.09.046","article-title":"Cerebrovascular accidents in ranibizumab","volume":"116","author":"Ueta","year":"2009","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.002_bib0051","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin\u00ae): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.002_bib0052","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/19466315.2015.1043395","article-title":"The FDA\u2019s final rule on Expedited Safety reporting: statistical considerations","volume":"7","author":"Wittes","year":"2015","journal-title":"Stat Biopharm Res"},{"issue":"12","key":"10.1016\/j.ajo.2026.09.002_bib0053","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/OPX.0b013e3182775c62","article-title":"Blood pressure, vessel caliber, and retinal thickness in diabetes","volume":"89","author":"Harrison","year":"2012","journal-title":"Optom Vis Sci"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:08:16Z","timestamp":1794301696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426005040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":53,"alternative-id":["S0002939426005040"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.09.002","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Applicability of Anti-VEGF Trial Criteria for Diabetic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}